Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life

The treatment paradigm in older patients with malignant hemopathies is the choice between an effective conservative treatment that preserves quality of life and an intensive, potentially curative treatment with more toxicities. For each patient, it is important to determine the risk/benefit ratio. T...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 15; no. 22; p. 5381
Main Authors Massaro, Fulvio, Andreozzi, Fabio, Vandevoorde, Charlotte, Bron, Dominique
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.11.2023
Subjects
Online AccessGet full text
ISSN2072-6694
2072-6694
DOI10.3390/cancers15225381

Cover

More Information
Summary:The treatment paradigm in older patients with malignant hemopathies is the choice between an effective conservative treatment that preserves quality of life and an intensive, potentially curative treatment with more toxicities. For each patient, it is important to determine the risk/benefit ratio. The patient should be involved in the discussion, sufficiently informed and able to express himself and his expectations in terms of quality of life. However, this informed consent is conditioned by the ability of the patient to understand the risks and benefits of the treatment. Decline in quality of life is an important parameter for older patients with cancer and many prospective trials have now confirmed the impact of different side effects of treatment, such as recurrent hospitalization, loss of autonomy in daily activities, loss of contact with grandchildren and loss of cognitive functions. Interventions oriented to vulnerabilities detected in the older patients (by comprehensive geriatric assessment) and an optimal approach, including preventive measures to reduce treatment-related toxicity and mortality, are directly correlated to improvement in quality of life.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15225381